Shire to Establish Rare Disease Innovation Hub in Cambridge
News Nov 24, 2016
Shire plc has announced that it will expand its operations in Cambridge, Massachusetts, establishing a rare disease innovation hub and increasing its footprint in the heart of Kendall Square. Shire and BioMed Realty have signed a lease for a 343,000-square-foot building at 500 Kendall Street. Shire’s lease begins in Q3, 2018, with occupancy anticipated for Q1, 2019.
With the adjacent space it currently occupies at 650 Kendall St., Shire will create a cross-disciplinary Kendall Square campus, with teams spanning research, clinical development, medical affairs, business development, and other related functions. Close coordination among these teams and with potential external partners will further catalyze Shire’s serial innovation across a range of rare diseases and highly specialized conditions.
“By expanding our presence in Cambridge, with its close proximity to best-in-class hospitals, research institutions, universities and a thriving biotechnology community, we will strengthen our ties with the early innovators around us to shape the next generation of breakthrough therapies for patients with high unmet needs,” said Shire Chief Executive Officer Flemming Ornskov, M.D., M.P.H.
“These plans signify our continued growth and our deep and enduring commitment to serving patients, families and caregivers across the globe who are affected by rare diseases and highly specialized conditions.” Shire will retain its current office, laboratory, and manufacturing space in Massachusetts, including its growing presence in Lexington, where it has been located since 2007. Shire currently employs more than 3,000 people in Massachusetts, and has increased the number of employees in the state by more than 670 percent in the past 11 years, including the creation of more than 700 new jobs in 2015 alone.
The company currently occupies more than two million square feet in Massachusetts. As part of its planned growth in Kendall Square, Shire is undertaking a strategic review to identify which specific functions and individuals will be located there over time. Per its website, the company is actively hiring, with nearly 400 positions currently designated for Massachusetts.
“I am thrilled that Shire will continue to grow in Massachusetts,” said Massachusetts Governor Charlie Baker. “Shire’s commitment to significantly expanding its Kendall Square innovation hub is a testament to the creativity of our state’s workforce, and to the competitiveness of the Commonwealth’s economy.”
Source: Story from Shire plc. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE